The Pennant Group has had an eventful week — a blowout Q1 print drove the stock up 13%, analysts lifted targets across the board, and short sellers retreated sharply. Then, on Wednesday, the Centers for Medicare & Medicaid Services announced six-month moratoria on new hospice and home health agency registrations, citing fraud prevention. That headline landed just as the post-earnings rally was consolidating, giving investors a new tension to weigh.
The Q1 earnings reaction was the dominant event. The stock surged roughly 13.6% on May 6 after results, and another 10.4% the following day — an unusually strong two-day response. The full week shows PNTG up 12.6% to $35.42, with a one-month gain now running at 15.5%. The CMS moratoria announcement on May 13 adds a potential regulatory headwind to an otherwise buoyant setup, since hospice and home health are central to Pennant's operating model. Whether the moratoria materially affects growth plans — or represents a competitive moat against new entrants — will be the key question for investors through August.
Short interest tells a clear story of capitulation. Positioned at roughly 1.9% of free float as of May 12, the short book has shrunk by 16% over the past week and is down 38% from a month ago. In early April, short interest was closer to 3% of float; the collapse through earnings was swift. Borrowing costs are negligible at 0.5% annualised, and availability in the lending market remains broad — well within normal ranges. There is no squeeze dynamic in play. The ORTEX short score has also eased, dropping from near 34.3 to 32.5 over the past week, consistent with short-side momentum fading rather than building.
The Street is firmly onside. RBC Capital, Truist Securities, and Wells Fargo all raised price targets on May 8, the day after earnings, with targets clustering at $41–$42 against the current price of $35.42. That puts the mean analyst target at roughly $40.33, implying around 14% return potential from current levels. Every firm maintained a positive rating — Outperform, Buy, and Overweight respectively — without any downgrades or hesitation. EPS momentum factor scores support the bullish read: 30-day EPS momentum ranks in the 74th percentile, and the 12-month forward EPS growth indicator sits at the 79th percentile. Valuation has moved up with the stock — the forward P/E is now at 24.6x, up roughly 2x over the past 30 days — but the Street has responded by lifting targets rather than trimming ratings.
Institutional ownership adds an interesting wrinkle. Wasatch Advisors added 835,000 shares in Q1, a very large build for a stock this size, bringing its holding to 4.1% of shares outstanding. FMR (Fidelity) added nearly 193,000 shares through April, while BlackRock added around 52,000. Van Berkom, the second-largest holder, trimmed by 446,000 shares over the same period — the most notable reduction in the top-15. Columbia Management and Wellington Management both built positions meaningfully in recent months. The institutional picture is broadly accumulative, with a few selective trims at the margin.
Options positioning remains lightly speculative. The put/call ratio has risen modestly to 0.032 — still very low in absolute terms, but about one standard deviation above its 20-day average, suggesting a small uptick in hedging activity since earnings. It is nowhere near the 52-week high of 0.93, and absolute option volumes on PNTG are thin enough that small changes in open interest move the ratio materially.
The next earnings date is August 6. Between now and then, the CMS hospice and home health moratoria — framed as a fraud crackdown — is the primary catalyst to track. Management commentary on whether the restrictions limit Pennant's new agency registrations or consolidation pipeline will set the tone heading into Q2.
See the live data behind this article on ORTEX.
Open PNTG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
